These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Structural assessment of HLA-A2-restricted SARS-CoV-2 spike epitopes recognized by public and private T-cell receptors. Wu D; Kolesnikov A; Yin R; Guest JD; Gowthaman R; Shmelev A; Serdyuk Y; Dianov DV; Efimov GA; Pierce BG; Mariuzza RA Nat Commun; 2022 Jan; 13(1):19. PubMed ID: 35013235 [TBL] [Abstract][Full Text] [Related]
6. A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection. Augusto DG; Murdolo LD; Chatzileontiadou DSM; Sabatino JJ; Yusufali T; Peyser ND; Butcher X; Kizer K; Guthrie K; Murray VW; Pae V; Sarvadhavabhatla S; Beltran F; Gill GS; Lynch KL; Yun C; Maguire CT; Peluso MJ; Hoh R; Henrich TJ; Deeks SG; Davidson M; Lu S; Goldberg SA; Kelly JD; Martin JN; Vierra-Green CA; Spellman SR; Langton DJ; Dewar-Oldis MJ; Smith C; Barnard PJ; Lee S; Marcus GM; Olgin JE; Pletcher MJ; Maiers M; Gras S; Hollenbach JA Nature; 2023 Aug; 620(7972):128-136. PubMed ID: 37468623 [TBL] [Abstract][Full Text] [Related]
7. Three Specific Potential Epitopes That Could Be Recognized by T Cells of Convalescent COVID-19 Patients Were Identified From Spike Protein. Zhang Y; Yang Z; Tang M; Li H; Tang T; Li G; Zhong Y; Zhang X; Wang X; Wang C Front Immunol; 2022; 13():752622. PubMed ID: 35154095 [TBL] [Abstract][Full Text] [Related]
8. In silico analysis suggests less effective MHC-II presentation of SARS-CoV-2 RBM peptides: Implication for neutralizing antibody responses. Castro A; Ozturk K; Zanetti M; Carter H PLoS One; 2021; 16(2):e0246731. PubMed ID: 33571241 [TBL] [Abstract][Full Text] [Related]
9. The HLA-II immunopeptidome of SARS-CoV-2. Weingarten-Gabbay S; Chen DY; Sarkizova S; Taylor HB; Gentili M; Hernandez GM; Pearlman LR; Bauer MR; Rice CM; Clauser KR; Hacohen N; Carr SA; Abelin JG; Saeed M; Sabeti PC Cell Rep; 2024 Jan; 43(1):113596. PubMed ID: 38117652 [TBL] [Abstract][Full Text] [Related]
10. Identification and validation of 174 COVID-19 vaccine candidate epitopes reveals low performance of common epitope prediction tools. Prachar M; Justesen S; Steen-Jensen DB; Thorgrimsen S; Jurgons E; Winther O; Bagger FO Sci Rep; 2020 Nov; 10(1):20465. PubMed ID: 33235258 [TBL] [Abstract][Full Text] [Related]
11. Broadly directed SARS-CoV-2-specific CD4+ T cell response includes frequently detected peptide specificities within the membrane and nucleoprotein in patients with acute and resolved COVID-19. Heide J; Schulte S; Kohsar M; Brehm TT; Herrmann M; Karsten H; Marget M; Peine S; Johansson AM; Sette A; Lütgehetmann M; Kwok WW; Sidney J; Schulze Zur Wiesch J PLoS Pathog; 2021 Sep; 17(9):e1009842. PubMed ID: 34529740 [TBL] [Abstract][Full Text] [Related]
12. Immunoinformatic approach to assess SARS-CoV-2 protein S epitopes recognised by the most frequent MHC-I alleles in the Brazilian population. Moura RR; Agrelli A; Santos-Silva CA; Silva N; Assunção BR; Brandão L; Benko-Iseppon AM; Crovella S J Clin Pathol; 2021 Aug; 74(8):528-532. PubMed ID: 32759312 [TBL] [Abstract][Full Text] [Related]
13. PopCover-2.0. Improved Selection of Peptide Sets With Optimal HLA and Pathogen Diversity Coverage. Nilsson JB; Grifoni A; Tarke A; Sette A; Nielsen M Front Immunol; 2021; 12():728936. PubMed ID: 34484239 [TBL] [Abstract][Full Text] [Related]
14. Distinguishing Signal From Noise in Immunopeptidome Studies of Limiting-Abundance Biological Samples: Peptides Presented by I-A Nanaware PP; Jurewicz MM; Clement CC; Lu L; Santambrogio L; Stern LJ Front Immunol; 2021; 12():658601. PubMed ID: 33995376 [TBL] [Abstract][Full Text] [Related]
15. Influence of HLA Class II Polymorphism on Predicted Cellular Immunity Against SARS-CoV-2 at the Population and Individual Level. Copley HC; Gragert L; Leach AR; Kosmoliaptsis V Front Immunol; 2021; 12():669357. PubMed ID: 34349756 [TBL] [Abstract][Full Text] [Related]
16. NF9 peptide specific cytotoxic T lymphocyte clone cross react to Y453F mutation of SARS-CoV-2 virus spike protein. Murai A; Kubo T; Ohkuri T; Yanagawa J; Yajima Y; Kosaka A; Li D; Nagato T; Murata K; Kanaseki T; Tsukahara T; Nagasaki T; Hirohashi Y; Kobayashi H; Torigoe T Immunol Med; 2024 Jun; 47(2):93-99. PubMed ID: 38236134 [TBL] [Abstract][Full Text] [Related]
17. Structural definition of HLA class II-presented SARS-CoV-2 epitopes reveals a mechanism to escape pre-existing CD4 Chen Y; Mason GH; Scourfield DO; Greenshields-Watson A; Haigh TA; Sewell AK; Long HM; Gallimore AM; Rizkallah P; MacLachlan BJ; Godkin A Cell Rep; 2023 Aug; 42(8):112827. PubMed ID: 37471227 [TBL] [Abstract][Full Text] [Related]
18. Broadly recognized, cross-reactive SARS-CoV-2 CD4 T cell epitopes are highly conserved across human coronaviruses and presented by common HLA alleles. Becerra-Artiles A; Calvo-Calle JM; Co MD; Nanaware PP; Cruz J; Weaver GC; Lu L; Forconi C; Finberg RW; Moormann AM; Stern LJ Cell Rep; 2022 Jun; 39(11):110952. PubMed ID: 35675811 [TBL] [Abstract][Full Text] [Related]
19. HLA class I-associated expansion of TRBV11-2 T cells in multisystem inflammatory syndrome in children. Porritt RA; Paschold L; Rivas MN; Cheng MH; Yonker LM; Chandnani H; Lopez M; Simnica D; Schultheiß C; Santiskulvong C; Van Eyk J; McCormick JK; Fasano A; Bahar I; Binder M; Arditi M J Clin Invest; 2021 May; 131(10):. PubMed ID: 33705359 [TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 spike protein-derived immunogenic peptides that are promiscuously presented by several HLA-class II molecules and their potential for inducing acquired immunity. Yajima Y; Kosaka A; Ohkuri T; Hirohashi Y; Li D; Nagasaki T; Nagato T; Torigoe T; Kobayashi H Heliyon; 2023 Sep; 9(9):e20192. PubMed ID: 37809871 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]